Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Arcturus Therapeutics Holdings Inc ARCT

Healthcare Biotechnology
Arcturus Therapeutics Holdings Inc. is a global messenger RNA medicines and vaccine company. The Company is focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases. In addition to its messenger RNA (mRNA) platform, its lipid nanoparticle (LNP) delivery system, LUNAR, has the potential to enable multiple nucleic acid... see more

Recent & Breaking News (NDAQ:ARCT)

Arcturus Therapeutics Announces Third Quarter Financial Results and Provides Corporate Update

GlobeNewswire November 7, 2019

Arcturus Therapeutics Expands Platform with STARR Technology(TM)

GlobeNewswire November 7, 2019

Arcturus Therapeutics to Report Corporate Overview and Financial Results on November 7th

GlobeNewswire November 4, 2019

Arcturus Therapeutics to Present at Three Upcoming Investor Conferences

GlobeNewswire October 2, 2019

Arcturus Therapeutics Announces $9.8 Million Registered Direct Offering of Common Stock

GlobeNewswire September 26, 2019

Arcturus Therapeutics Announces Appointment of Dr. Edward Holmes M.D. and Re-Appointment of Andy Sassine to the Board of Directors

GlobeNewswire September 23, 2019

Arcturus Therapeutics To Present at Two Investor Conferences in September

GlobeNewswire August 26, 2019

Arcturus Therapeutics Announces Second Quarter Financial Results and Provides a Corporate Update

GlobeNewswire August 15, 2019

Arcturus to Report Corporate Overview and Financial Results on August 15

GlobeNewswire August 7, 2019

Arcturus Therapeutics Announces $2.3 Million Additional Registered Direct Offering of Common Stock

GlobeNewswire August 2, 2019

Arcturus Therapeutics Announces $10.9 Million Registered Direct Offering of Common Stock

GlobeNewswire August 1, 2019

Arcturus Therapeutics Receives up to $15 Million Commitment from the Cystic Fibrosis Foundation to Create mRNA Therapies to Treat Cystic Fibrosis Patients

GlobeNewswire August 1, 2019

Evolus Expands Board of Directors with Appointment of Independent Directors Peter Farrell, Ph.D. and Karah Parschauer, J.D.

GlobeNewswire July 15, 2019

Arcturus Therapeutics to Participate in Two Panels at the ROTH RNA Revolution Conference

GlobeNewswire July 10, 2019

Arcturus Therapeutics Receives Orphan Drug Designation from the U.S. FDA for ARCT-810, for Treatment of Ornithine Transcarbamylase (OTC) Deficiency

GlobeNewswire June 27, 2019

Ultragenyx and Arcturus Therapeutics Expand Existing Research Collaboration and License Agreement to Develop Additional Nucleic Acid Therapies for Rare Diseases

GlobeNewswire June 19, 2019

Arcturus Therapeutics Announces Redomiciliation to the United States as a Delaware Corporation

GlobeNewswire June 13, 2019

Arcturus Therapeutics Presenting Data for ARCT-810 and the Arcturus mRNA + LUNAR® Technology Platform at the 2019 Annual Meeting of TIDES: Oligonucleotide and Peptide Therapeutics

GlobeNewswire May 20, 2019

Arcturus Therapeutics Announces First Quarter Financial Results and Provides a Corporate Update

GlobeNewswire May 13, 2019

71 Biggest Movers From Yesterday

Benzinga.com  March 28, 2019